Literature DB >> 12098591

Lack of reward and locomotor stimulation induced by heroin in mu-opioid receptor-deficient mice.

Angelo Contarino1, Roberto Picetti, Hans W Matthes, George F Koob, Brigitte L Kieffer, Lisa H Gold.   

Abstract

The micro-opioid receptor is the main substrate mediating opiate reward. Multiple micro-opioid receptor subtypes have been postulated to underlie opiate actions. Animals treated with antisense oligonucleotides targeting specific micro-opioid receptor exons show differential sensitivity to morphine versus heroin. The present work examined the rewarding and locomotor activating effects of heroin in mutant mice with a disrupted exon 2 of the micro-opioid receptor. Heroin (1-3 mg/kg) produced significant place preferences and stimulated locomotor activity in wild-type mice, whereas it had no effect in micro-opioid receptor-deficient mice. In contrast, treatment with cocaine (10-30 mg/kg) produced comparable place preferences and locomotor activation in both wild-type and micro-opioid receptor-deficient mice, thus providing evidence that the mutant mice are able to show drug-induced effects in the two behavioral paradigms used here. These results support an essential role for the micro-opioid receptor in the rewarding and locomotor activating effects of heroin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12098591     DOI: 10.1016/s0014-2999(02)01812-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  25 in total

Review 1.  Non-nociceptive roles of opioids in the CNS: opioids' effects on neurogenesis, learning, memory and affect.

Authors:  Cherkaouia Kibaly; Chi Xu; Catherine M Cahill; Christopher J Evans; Ping-Yee Law
Journal:  Nat Rev Neurosci       Date:  2019-01       Impact factor: 34.870

2.  Modified 'Joyce model' of opioid dependence/withdrawal.

Authors:  Robert B Raffa; Ronald J Tallarida
Journal:  Eur J Pharmacol       Date:  2006-09-16       Impact factor: 4.432

3.  Modification of morphine-induced hyperlocomotion and antinociception in mice by clorgyline, a monoamine oxidase-A inhibitor.

Authors:  Nobue Kitanaka; Junichi Kitanaka; Motohiko Takemura
Journal:  Neurochem Res       Date:  2006-06-23       Impact factor: 3.996

Review 4.  The neurocircuitry of addiction: an overview.

Authors:  M W Feltenstein; R E See
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

5.  Mu opioid receptor knockdown in the substantia nigra/ventral tegmental area by synthetic small interfering RNA blocks the rewarding and locomotor effects of heroin.

Authors:  Y Zhang; M Landthaler; S D Schlussman; V Yuferov; A Ho; T Tuschl; M J Kreek
Journal:  Neuroscience       Date:  2008-10-02       Impact factor: 3.590

6.  HS014, a selective melanocortin-4 (MC4) receptor antagonist, modulates the behavioral effects of morphine in mice.

Authors:  N Eser Ercil; Ruggero Galici; Robert A Kesterson
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

Review 7.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

Review 8.  Alterations in the levels of heterotrimeric G protein subunits induced by psychostimulants, opiates, barbiturates, and ethanol: Implications for drug dependence, tolerance, and withdrawal.

Authors:  Nobue Kitanaka; Junichi Kitanaka; F Scott Hall; Tomohiro Tatsuta; Yoshio Morita; Motohiko Takemura; Xiao-Bing Wang; George R Uhl
Journal:  Synapse       Date:  2008-09       Impact factor: 2.562

Review 9.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

10.  Interaction of the mu-opioid receptor with GPR177 (Wntless) inhibits Wnt secretion: potential implications for opioid dependence.

Authors:  Jay Jin; Saranya Kittanakom; Victoria Wong; Beverly A S Reyes; Elisabeth J Van Bockstaele; Igor Stagljar; Wade Berrettini; Robert Levenson
Journal:  BMC Neurosci       Date:  2010-03-09       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.